109 related articles for article (PubMed ID: 10761168)
1. Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury.
Segal JL; Hayes KC; Brunnemann SR; Hsieh JT; Potter PJ; Pathak MS; Tierney DS; Mason D
J Clin Pharmacol; 2000 Apr; 40(4):402-9. PubMed ID: 10761168
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.
Hayes KC; Potter PJ; Hsieh JT; Katz MA; Blight AR; Cohen R
Arch Phys Med Rehabil; 2004 Jan; 85(1):29-34. PubMed ID: 14970964
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.
Hayes KC; Potter PJ; Hansebout RR; Bugaresti JM; Hsieh JT; Nicosia S; Katz MA; Blight AR; Cohen R
Clin Neuropharmacol; 2003; 26(4):185-92. PubMed ID: 12897638
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
Potter PJ; Hayes KC; Segal JL; Hsieh JT; Brunnemann SR; Delaney GA; Tierney DS; Mason D
J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.
Hayes KC; Katz MA; Devane JG; Hsieh JT; Wolfe DL; Potter PJ; Blight AR
J Clin Pharmacol; 2003 Apr; 43(4):379-85. PubMed ID: 12723458
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
Vollmer T; Henney HR
Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
[TBL] [Abstract][Full Text] [Related]
7. The use of 4-aminopyridine (fampridine) in demyelinating disorders.
Hayes KC
CNS Drug Rev; 2004; 10(4):295-316. PubMed ID: 15592580
[TBL] [Abstract][Full Text] [Related]
8. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
Cardenas DD; Ditunno JF; Graziani V; McLain AB; Lammertse DP; Potter PJ; Alexander MS; Cohen R; Blight AR
Spinal Cord; 2014 Jan; 52(1):70-6. PubMed ID: 24216616
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
Vollmer T; Blight AR; Henney HR
Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Cardenas DD; Ditunno J; Graziani V; Jackson AB; Lammertse D; Potter P; Sipski M; Cohen R; Blight AR
Spinal Cord; 2007 Feb; 45(2):158-68. PubMed ID: 16773037
[TBL] [Abstract][Full Text] [Related]
11. 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury.
Segal JL; Brunnemann SR
Pharmacotherapy; 1997; 17(3):415-23. PubMed ID: 9165545
[TBL] [Abstract][Full Text] [Related]
12. Fampridine-SR for multiple sclerosis and spinal cord injury.
Hayes KC
Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
[TBL] [Abstract][Full Text] [Related]
13. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients.
Hansebout RR; Blight AR; Fawcett S; Reddy K
J Neurotrauma; 1993; 10(1):1-18. PubMed ID: 8320728
[TBL] [Abstract][Full Text] [Related]
14. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Smith W; Swan S; Marbury T; Henney H
J Clin Pharmacol; 2010 Feb; 50(2):151-9. PubMed ID: 19966074
[TBL] [Abstract][Full Text] [Related]
15. Lipid profile in spinal cord-injured women with different injury levels.
Storch MJ; König D; Bültermann D; Blum A; Vogt S; Baumstark M; Berg A; Schmid A
Prev Med; 2005 Mar; 40(3):321-5. PubMed ID: 15533546
[TBL] [Abstract][Full Text] [Related]
16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
17. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial.
Wolfe DL; Hayes KC; Hsieh JT; Potter PJ
J Neurotrauma; 2001 Aug; 18(8):757-71. PubMed ID: 11526982
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial.
Segal JL; Pathak MS; Hernandez JP; Himber PL; Brunnemann SR; Charter RS
Pharmacotherapy; 1999 Jun; 19(6):713-23. PubMed ID: 10391417
[TBL] [Abstract][Full Text] [Related]
19. Spinal cord injury level and the circulating cytokine response to strenuous exercise.
Paulson TA; Goosey-Tolfrey VL; Lenton JP; Leicht CA; Bishop NC
Med Sci Sports Exerc; 2013 Sep; 45(9):1649-55. PubMed ID: 23475168
[TBL] [Abstract][Full Text] [Related]
20. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury.
Qiao J; Hayes KC; Hsieh JT; Potter PJ; Delaney GA
J Neurotrauma; 1997 Mar; 14(3):135-49. PubMed ID: 9104931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
